Search Results - "Partin, A W"

Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy by Schweizer, M.T., Zhou, X.C., Wang, H., Yang, T., Shaukat, F., Partin, A.W., Eisenberger, M.A., Antonarakis, E.S.

“…Clinical trials in men with biochemically recurrent prostate cancer (BRPC) have been hampered by long survival times, making overall survival (OS) a difficult…”
Get full text

Very-high-risk localized prostate cancer: definition and outcomes by Sundi, D, Wang, V M, Pierorazio, P M, Han, M, Bivalacqua, T J, Ball, M W, Antonarakis, E S, Partin, A W, Schaeffer, E M, Ross, A E

“…Background: Outcomes in men with National Comprehensive Cancer Network (NCCN) high-risk prostate cancer (PCa) can vary substantially—some will have excellent…”
Get full text

Natural History of Progression After PSA Elevation Following Radical Prostatectomy by Pound, Charles R, Partin, Alan W, Eisenberger, Mario A, Chan, Daniel W, Pearson, Jay D, Walsh, Patrick C

“…CONTEXT In men who develop an elevated serum prostate-specific antigen level (PSA) after having undergone a radical prostatectomy, the natural history of…”
Get full text

Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years by Walsh, P C, Partin, A W, Epstein, J I

“…The experience after 10 years with anatomical radical retropubic prostatectomy at The Johns Hopkins Hospital is reviewed. Between April 1982 and March 1991,…”
Get more information

The effect of hospital volume on cancer control after radical prostatectomy by Ellison, L M, Trock, B J, Poe, N R, Partin, A W

“…For complex oncological procedures, hospital volume affects short and long-term patient outcome. We examined the association of hospital volume and long-term…”
Get more information

The clinical usefulness of prostate specific antigen: update 1994 by Partin, A W, Oesterling, J E

“…In conclusion, PSA is the first prostate specific serum marker of clinical usefulness in urology. It represents a valuable clinical tool that has improved our…”
Get more information

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer by Partin, A W, Yoo, J, Carter, H B, Pearson, J D, Chan, D W, Epstein, J I, Walsh, P C

“…Clinical stage, Gleason score and serum prostate specific antigen (PSA) levels are used separately to predict pathological stage in patients with localized…”
Get more information

Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial by Catalona, William J, Partin, Alan W, Slawin, Kevin M, Brawer, Michael K, Flanigan, Robert C, Patel, Anup, Richie, Jerome P, deKernion, Jean B, Walsh, Patrick C, Scardino, Peter T, Lange, Paul H, Subong, Eric N. P, Parson, Robert E, Gasior, Gail H, Loveland, Kathleen G, Southwick, Paula C

“…CONTEXT.— The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer…”
Get full text

The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens : A proposal to modify the Gleason grading system by PAN, C.-C, POTTER, S. R, PARTIN, A. W, EPSTEIN, J. I

“…The Gleason grading system of prostatic adenocarcinoma does not account for the existence of a tertiary (third most prevalent) pattern, and there are no…”
Get full text

Prediction of progression following radical prostatectomy : A multivariate analysis of 721 men with long-term follow-up by EPSTEIN, J. I, PARTIN, A. W, SAUVAGEOT, J, WALSH, P. C

“…We studied 721 men with clinically confined disease who underwent radical prostatectomy. No patient received preoperative or postoperative radiotherapy or…”
Get full text

Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging by Catalona, William J, Southwick, Paula C, Slawin, Kevin M, Partin, Alan W, Brawer, Michael K, Flanigan, Robert C, Patel, Anup, Richie, Jerome P, Walsh, Patrick C, Scardino, Peter T, Lange, Paul H, Gasior, Gail H, Loveland, Kathleen G, Bray, Kurtis R

“…Objectives. Various methods have been proposed to increase the specificity of prostate-specific antigen (PSA), including age-specific PSA reference ranges, PSA…”
Get full text

Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years by Partin, A W, Pound, C R, Clemens, J Q, Epstein, J I, Walsh, P C

“…1. With an average follow-up of 53 months (range 12-120 months), 19.4% (185/955) of men have had a cancer recurrence after radical prostatectomy for clinically…”
Get more information

Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies by Hansel, D E, DeMarzo, A M, Platz, E A, Jadallah, S, Hicks, J, Epstein, J I, Partin, A W, Netto, G J

“…Early prostate cancer antigen is a nuclear matrix protein that was recently shown to be expressed in prostate adenocarcinoma and adjacent benign tissue…”
Get more information

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control by Pound, C R, Partin, A W, Epstein, J I, Walsh, P C

“…In a series of 1623 men with a follow-up of 5 +/- 3 years (range 1-13) after anatomic RRP for clinically localized prostate cancer, 17% (276/1623) have shown…”
Get more information

Prostate specific antigen: a decade of discovery--what we have learned and where we are going by Polascik, T J, Oesterling, J E, Partin, A W

“…Many advances have occurred during the last decade in the clinical use of prostate specific antigen (PSA) for detecting, staging and monitoring prostate…”
Get more information

Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer by Manyak, Michael J., Hinkle, George H., Olsen, John O., Chiaccherini, Richard P., Partin, Alan W., Piantadosi, Steven, Burgers, John K., Texter, John H., Neal, Charles E., Libertino, John A., Wright, George L., Maguire, Robert T.

“…Objectives. No standard noninvasive diagnostic test reliably differentiates patients with organ-confined prostate cancer from those with lymph node metastases…”
Get full text

Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters by Epstein, Jonathan I, Partin, Alan W, Potter, Steven R, Walsh, Patrick C

“…Objectives. To stratify the prognosis of lymph node-negative, seminal vesicle-positive tumors in men with prostate cancer after radical retropubic…”
Get full text

Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup by Epstein, J I, Carmichael, M, Partin, A W, Walsh, P C

“…Tumor volume has been shown to be proportionate to Gleason grade, capsular penetration, seminal vesicle invasion, lymph node metastases and capsular margins of…”
Get more information

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer by Woodrum, D L, Brawer, M K, Partin, A W, Catalona, W J, Southwick, P C

“…We reviewed the use of percent free prostate specific antigen (PSA) to enhance specificity of PSA testing and aid in the discrimination of benign and malignant…”
Get more information

Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF by Gretzer, M.B., Chan, D.W., van Rootselaar, C.L., Rosenzweig, J.M., Dalrymple, S., Mangold, L.A., Partin, A.W., Veltri, R.W.

“…Background Surface enhanced laser desorption and ionization‐time‐of‐flight (SELDI‐TOF) is an evolving proteomic technology for improving biomarker discovery…”
Get full text